# Nephrology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emily Dickinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI023-SYN
- Date: 2026-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucinda Hartwell, MD
- Calendar frame: modern shifted

- To: Samuel Adeyemi, MD, Nephrology
- Urgency: Routine, within four weeks; please see her on the same morning as her kidney ultrasound, since she travels with difficulty

## Referral question

Stage G3a A2 chronic kidney disease with hypertension in a 54-year-old woman without diabetes. Please confirm the probable cause, advise whether further tests are needed, and advise on kidney-protective treatment and follow-up. **S**

## Questions for the consultant

1. Is hypertensive kidney disease the probable cause, or does she need further tests, such as serology or a kidney biopsy?
2. Should she take an SGLT2 inhibitor, given that she does not have diabetes?
3. What ARB dose and blood pressure target do you advise?
4. How should the raised PTH and low vitamin D be managed at this stage?
5. How often does she need nephrology follow-up, and can it be by video?

## Pertinent history

Several months of morning headaches, nausea, and tiredness. Blood pressure 166/98 mmHg at today's home visit; she has never been treated for hypertension. She has taken over-the-counter naproxen several times a week for the headaches, stopped today. An urgent care visit fourteen months ago recorded an eGFR of 58 and a urine albumin-creatinine ratio of 190 mg/g, which were not followed up. Today: creatinine 1.20 mg/dL (eGFR 54), potassium 4.4 mmol/L, urine albumin-creatinine ratio 240 mg/g, urine red cells 1 per high-power field, hemoglobin 12.3 g/dL, calcium 9.3 and phosphate 3.8 mg/dL, PTH 74 pg/mL, 25-hydroxyvitamin D 21 ng/mL, HbA1c 5.5 percent, LDL 134 mg/dL. KFRE 0.5 percent at 2 years and 1.6 percent at 5 years. ECG shows borderline voltage for left ventricular hypertrophy. Started today: losartan 50 mg, atorvastatin 20 mg, vitamin D3 1,000 units, and acetaminophen as needed. Never smoker; no alcohol. She has long wished to stay at home and asks for as few clinic trips as possible; video follow-up suits her. **S**

- Emily Dickinson was born on December 10, 1830, in the family Homestead on Main Street in Amherst, Massachusetts. **D**
- In the late winter of 1848 she was removed from Mount Holyoke Female Seminary for about a month because of lung congestion and a cough. **D**
- In 1851 she had symptoms then thought to be consumptive, consulted local and Boston doctors, and for two years took a glycerine prescription from a Boston tuberculosis specialist until the symptoms apparently subsided. **D**
- By her own account an eye affliction began in the fall of 1863; in February 1864 she consulted the Boston ophthalmologist Henry Willard Williams, lived in Cambridgeport from April to December 1864 to be near him for treatment, and repeated the treatment from April to October 1865, after which she was apparently cured. **D**
- The treatment required confinement in dim light, no reading, and writing only in pencil; she called her first stay in Cambridge eight months of Siberia. **D**
- No record of the eye diagnosis survives. Her main symptoms were sensitivity to light, aching eyes, and a restricted ability to do close work; iritis is considered the most likely explanation, and exotropia, a psychiatric cause, and hysterical hyperaesthesia of the retina have also been proposed. **R**
- Her withdrawal from normal social situations began in her mid-twenties; in later years she rarely went beyond the family Homestead and spoke with some visitors from behind a darkened door rather than face to face. **D**
- Scholars disagree whether her withdrawal was a deliberate artistic choice or had a medical origin, such as an anxiety condition. **R**
- A 2013 review by Hirschhorn and Longsworth rejects a proposed diagnosis of epilepsy on scientific, clinical, and biographical grounds. **R**
- Her death came after two and a half years of ill health that followed a death in her family in October 1883 and a consequent nervous prostration; she later had two blackouts and was confined to bed for the seven months before her death. **D**
- Her letters mention severe headache and nausea, and her last illness ended in a coma with raspy, difficult breathing. **D**
- Her reclusiveness hampered her Amherst physician, because she would not admit him to her bedside to take a pulse. **D**
- Researchers have concluded that she died of heart failure caused by severe hypertension; no documentary evidence records the yellow pallor and odor associated with nephritis. **R**

1 later historical claim is omitted because it describes events after the index age. See the teaching note.

Baseline: Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 24 mmol/L; BUN: 21 mg/dL; Creatinine: 1.2 mg/dL (high); eGFR: 54 mL/min/1.73 m² (low); Glucose: 92 mg/dL; Calcium: 9.3 mg/dL; Phosphate: 3.8 mg/dL; Intact PTH: 74 pg/mL (high); 25-hydroxyvitamin D: 21 ng/mL (low); Albumin: 4.1 g/dL; Hemoglobin: 12.3 g/dL; Total cholesterol: 214 mg/dL (high); HDL cholesterol: 54 mg/dL; LDL cholesterol: 134 mg/dL (high); Triglycerides: 130 mg/dL; HbA1c: 5.5%; TSH: 2.1 mIU/L; Urine albumin-creatinine ratio: 240 mg/g (high); Urine red cells: 1 /[HPF]; KFRE 2-year kidney failure risk: 0.5%; KFRE 5-year kidney failure risk: 1.6%; PHQ-9: 6; GAD-7: 5. All results are synthetic.

BP 166/98 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 54 kg; BMI 20.3 kg/m². All vital signs are synthetic.

## Current medications

- Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**

## Plan so far

- Start losartan 50 mg daily and raise it to the maximum dose of 100 mg for A2 albuminuria; check potassium and creatinine 2 to 4 weeks after each start or increase, accepting a creatinine rise of up to 30 percent. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- If a second sample confirms a urine albumin-creatinine ratio of at least 200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily) after the nephrology review, and check potassium and creatinine 2 to 4 weeks later. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Stop naproxen and avoid all NSAIDs; acetaminophen for headache; check kidney function before any iodinated contrast; adjust drug doses to eGFR. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- CMID kidney and blood pressure monitoring: blood pressure every visit with home readings; eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; calcium, phosphate, and PTH every 6 to 12 months; vitamin D at baseline; hemoglobin and KFRE yearly; one lipid panel and a statin; medication review every visit; vaccines reviewed yearly. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Atorvastatin 20 mg daily; vitamin D3 1,000 units daily with recheck of 25-hydroxyvitamin D, calcium, phosphate, and PTH. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Vaccines for chronic kidney disease: PCV20 now, a two-dose hepatitis B series, and yearly influenza and COVID-19 vaccines. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026); Adult Immunization Schedule by Age (2026) **S**
- Home-centered care: home visits and video visits with her own validated blood pressure cuff, scale, thermometer, and pulse oximeter; mobile phlebotomy; clinic trips only for tests that need them, with several tasks booked on one quiet early appointment. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- PHQ-9 and GAD-7 at baseline and yearly; her long-standing wish for solitude is respected and not treated as a disorder unless symptoms cause distress or impairment. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026); Anxiety Disorders in Adults: Screening (2023); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Sodium below 2 g a day, a plant-rich diet, and at least 150 minutes a week of activity, such as garden work and walking. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
